Q32 Bio Shares Jump 60% After Positive Mid-Stage Alopecia Trial Results (QTTB)2026-07-1337%External coverage
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata2026-07-1313%External coverage
Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 20262026-07-100%External coverage